FIELD: biotechnology.
SUBSTANCE: invention relates to a multispecific antigen-binding protein, as well as an antigen-binding protein. Compositions and host cells for expression of said proteins are also disclosed. Invention also relates to a pharmaceutical composition for treating a disorder in which antigen activity has a negative effect.
EFFECT: invention enables effective heterodimerisation of antigen-binding proteins.
25 cl, 12 dwg, 11 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PSEUDO-FAB BASED MULTISPECIFIC BINDING PROTEINS | 2019 |
|
RU2820254C2 |
| ANTIBODY-LIKE BINDING PROTEINS WITH DOUBLE VARIABLE REGIONS HAVING CROSS-CROSS ORIENTATION OF BINDING REGIONS | 2012 |
|
RU2823693C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| ANTIBODIES BINDING TO GPRC5D | 2020 |
|
RU2841523C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
